Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
On June 30, 2025, Dr. Reddy’s Laboratories announced the release of its Integrated Annual Report for the financial year 2024-25. The report has been made available electronically to shareholders who have registered their email addresses, and a web link has been provided for those who have not. This move reflects the company’s commitment to transparency and regulatory compliance, potentially strengthening its relationship with stakeholders and enhancing its market position.
The most recent analyst rating on (RDY) stock is a Buy with a $19.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India, specializing in the development and manufacturing of generic medications. The company is listed on multiple stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 2,015,894
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.67B
Learn more about RDY stock on TipRanks’ Stock Analysis page.